✦ LIBER ✦

Clinical pharmacology of intermediate-dose oral methotrexate

✍ Scribed by D. K. Smith; G. A. Omura; F. Ostroy

Book ID: 112285964
Publisher: Springer
Year: 1980
Tongue: English
Weight: 399 KB
Volume: 4
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00254032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical pharmacology of oral intermedia

Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid

✍ Michael B. Lilly; George A. Omura 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 259 KB

The bioavailability of oral intermediate

The bioavailability of oral intermediate-dose methotrexate

✍ V. J. Harvey; M. L. Slevin; R. C. Woollard; A. Johnston; M. J. Barnett; P. F. M. 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 378 KB

The oral bioavailability of methotrexate is variable and may be dose-dependent. The absorption of 'interval' oral methotrexate, which is given between cycles of chemotherapy, is unknown. The bioavailability of oral methotrexate has been studied in eight patients, acting as their own controls, to ass

Clinical pharmacology of methotrexate

✍ Bertino, J. R. 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 746 KB

## Abstract Methotrexate (MTX), a potent folate antagonist by virtue of its ability to inhibit the enzyme dihydrofolate reductase [1], continues to be a useful cancer chemotherapeutic agent [2]. Information not only on its mechanism of action, but also its pharmacology has led to improved dosage sc

Oral consequences of low-dose methotrexa

Oral consequences of low-dose methotrexate

📂 Article 📅 2006 🏛 Elsevier Science ⚖ 128 KB

Opioids: clinical pharmacology: Clinical

Opioids: clinical pharmacology: Clinical pharmacology of hydromorphone hydrochloride extended-release capsules following multiple-dose oral administration

✍ V. Vashi; A. Cipriano; S. Harris; A. El-Tahtawy; D. Wu 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Oral mucositis and salivary methotrexate

Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia

✍ Ishii, Eiichi ;Yamada, Shin-Ichi ;Higuchi, Shun ;Honjo, Tetsu ;Igarashi, Hisaji 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 335 KB

The relationship between salivary methotrexate (MTX) concentration and severity of oral mucositis after administration of MTX was investigated in six children with acute lymphoblastic leukemia. They received two administrations of MTX at 500 mgm' with one third given bolusly and the remainder by 24-